Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 24;13:591475. doi: 10.3389/fnagi.2021.591475

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wilkaniec, Lenkiewicz, Babiec, Murawska, Jęśko, Cieślik, Culmsee and Adamczyk.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Parkin deregulation induced by α-Syn treatment decreases PGC1α expression in PC12 cells. (A) PGC1α immunoreactivity normalized to GAPDH in pcDNA and pcDNA-Parkin PC12 cells treated with α-Syn for 24 h at a concentration of 5 μM. Data were normalized to the untreated control group (=100%) and represent the mean value ± SD for eight independent experiments (n = 8). *p < 0.05, ***p < 0.001 compared to pcDNA control cells; ^###p < 0.001 compared to pcDNA cells treated with α-Syn, using two-way ANOVA followed by Bonferroni post hoc test. (B) PGC1α immunoreactivity normalized to GAPDH in Parkin knock-down PC12 cells. Data were normalized to the untreated control group (=100%) and represent the mean value ± SD for 10 independent experiments (n = 10). ***p < 0.001 compared to corresponding control siRNA, using Student’s t-test. (C) The mRNA level of Tfam in pcDNA and pcDNA-Parkin PC12 cells treated with α-Syn for 24 h at a concentration of 5 μM. The mRNA level was measured by real-time PCR and normalized to Actb (β-actin). Data represent the mean value ± SD for six independent experiments (n = 6). **p < 0.01, ***p < 0.001 compared to pcDNA control cells using two-way ANOVA followed by Bonferroni post hoc test. (D) The mRNA level of Tfam in Parkin knock-down PC12 cells. The mRNA level was measured by real-time PCR and normalized to Actb (β-actin). Data represent the mean value ± SD for four independent experiments (n = 4). (E) The mRNA level of Nrf-1 in pcDNA and pcDNA-Parkin PC12 cells treated with α-Syn for 24 h at a concentration of 5 μM. The mRNA level was measured by real-time PCR and normalized to Actb (β-actin). Data represent the mean value ± SD for six independent experiments (n = 6). **p < 0.01, ***p < 0.001 compared to pcDNA control cells using two-way ANOVA followed by Bonferroni post hoc test. (F) The mRNA level of Nrf-1 in Parkin knock-down PC12 cells. The mRNA level was measured by real-time PCR and normalized to Actb (β-actin). Data represent the mean value ± SD for four independent experiments (n = 4).